<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Colomb Med (Cali)</journal-id>
<journal-id journal-id-type="iso-abbrev">Colomb. Med</journal-id>
<journal-id journal-id-type="publisher-id">cm</journal-id>
<journal-title-group>
<journal-title>Colombia Médica : CM</journal-title>
</journal-title-group>
<issn pub-type="ppub">0120-8322</issn>
<issn pub-type="epub">1657-9534</issn>
<publisher>
<publisher-name>Universidad del Valle</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30410199</article-id>
<article-id pub-id-type="pmc">6220489</article-id>
<article-id pub-id-type="doi">10.25100/cm.v49i2.3802</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>LRBA in the endomembrane system</article-title>
<trans-title-group xml:lang="es">
<trans-title>LRBA en el sistema de endomembranas</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Martínez Jaramillo</surname>
<given-names>Catalina</given-names>
</name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Trujillo-Vargas</surname>
<given-names>Claudia M.</given-names>
</name>
</contrib>
<aff id="aff1">Grupo de Inmunodeficiencias primarias, Facultad de Medicina, Universidad de Antioquia UdeA, Medellín, Colombia.</aff>
</contrib-group>
<author-notes>
<corresp id="c1"><label>Corresponding author:</label> Claudia M. Trujillo-Vargas. Sede de Investigaciones Universitarias, Universidad de Antioquia, UdeA. Carrera 62 #52-59 Lab 530. E-mail: <email>claudia.trujillo@udea.edu.co</email></corresp>
<fn fn-type="COI-statement" id="fn2">
<p><bold>Conflic of interest: </bold> The authors declare no conflict of interest </p>
</fn>
</author-notes>
<pub-date date-type="pub" iso-8601-date="2018-09-30" publication-format="electronic">
<day>30</day>
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date date-type="collection" publication-format="electronic">
<season>Jul-Sep</season>
<year>2018</year>
</pub-date>
<volume>49</volume>
<issue>3</issue>
<fpage>236</fpage>
<lpage>243</lpage>
<history>
<date date-type="received">
<day>08</day>
<month>3</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>09</day>
<month>5</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>9</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018 Universidad del Valle</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="open-access">
<license-p>This article is distributed under the terms of the Creative Commons Attribution License <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<abstract>
<title>Abstract</title>
<p>Bi-allelic mutations in <italic>LRBA</italic> (from <italic>Lipopolysaccharide-responsive and beige-like anchor protein</italic>) result in a primary immunodeficiency with clinical features ranging from hypogammaglobulinemia and lymphoproliferative syndrome to inflammatory bowel disease and heterogeneous autoimmune manifestations. LRBA deficiency has been shown to affect vesicular trafficking, autophagy and apoptosis, which may lead to alterations of several molecules and processes that play key roles for immunity.</p>
<p>In this review, we will discuss the relationship of LRBA with the endovesicular system in the context of receptor trafficking, autophagy and apoptosis. Since these mechanisms of homeostasis are inherent to all living cells and not only limited to the immune system and also, because they are involved in physiological as well as pathological processes such as embryogenesis or tumoral transformation, we envisage advancing in the identification of potential pharmacological agents to manipulate these processes.</p>
</abstract>
<trans-abstract xml:lang="es">
<title>Resumen</title>
<p>Las mutaciones bi-alélicas en <italic>LRBA</italic> (del inglés, <italic>Lipopolysaccharide-responsive and beige-like anchor protein)</italic> conllevan a una inmunodeficiencia primaria con características clínicas que abarcan desde hipogamaglubulinemia y síndrome linfoproliferativo hasta una enfermedad inflamatoria intestinal y manifestaciones autoinmunes heterogéneas. Se ha demostrado que la deficiencia de LRBA afecta el tráfico vesicular, la autofagia y la apoptosis pudiendo generar alteraciones en la regulación de varios procesos importantes para la inmunidad. En esta revisión discutiremos la relación de LRBA con el sistema endovesicular en el contexto del tráfico de receptores, la autofagia y la apoptosis. Estos mecanismos de homeostasis son inherentes a todas las células y no están limitados a las células del sistema inmune, están involucrados en procesos fisiológicos y patológicos, como la embriogénesis o la transformación tumoral. El entendimiento de la función de LRBA permitirá avanzar en la identificación de los posibles blancos farmacológicos para manipular estos procesos.</p>
</trans-abstract>
<kwd-group>
<title>Keywords:</title>
<kwd>Primary immunodeficiencies</kwd>
<kwd>LRBA deficiency</kwd>
<kwd>vesicle trafficking</kwd>
<kwd>autophagy</kwd>
<kwd>apoptosis</kwd>
</kwd-group>
<kwd-group xml:lang="es">
<title>Palabras clave:</title>
<kwd>Inmunodeficiencias primarias</kwd>
<kwd>deficiencia de LRBA</kwd>
<kwd>tráfico vesicular</kwd>
<kwd>autofagia</kwd>
<kwd>apoptosis</kwd>
</kwd-group>
<counts>
<fig-count count="4"></fig-count>
<table-count count="2"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="57"></ref-count>
<page-count count="8"></page-count>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>More than 400 genes have been reported to affect the immune system either quantitative and/or qualitatively and also, in a symptomatic manner <xref ref-type="bibr" rid="B1">
<sup>1</sup>
</xref>
<sup>.</sup> Among them is included <italic>LRBA</italic> (<italic>Lipopolysaccharide-responsive and beige-like anchor protein</italic>); either homozygous or compound heterozygous mutations in this gene cause loss of LRBA protein expression, which is associated with a broad spectrum of clinical and immunological manifestations <xref ref-type="bibr" rid="B1">
<sup>1</sup>
</xref>. The first report on LRBA deficiency was performed in five patients from four consanguineous families with hypogammaglobulinemia, autoimmune manifestations and recurrent infections <xref ref-type="bibr" rid="B2">
<sup>2</sup>
</xref>.<sup>.</sup> Subsequently, several reports of individuals with LRBA deficiency have been published, who suffer from a wider spectrum of clinical manifestations including: increased susceptibility to infections, polyautoimmunity, lymphoproliferation and gastropathy, all associated or not with hypogamaglobulinemia <xref ref-type="bibr" rid="B3">
<sup>3</sup>
</xref>
<sup>-</sup>
<xref ref-type="bibr" rid="B5">
<sup>5</sup>
</xref>. Moreover, an asymptomatic individual has also been reported <xref ref-type="bibr" rid="B6">
<sup>6</sup>
</xref>.</p>
<p>With regard to the immunological findings, T lymphocytes from patients with the LRBA deficiency presented with an increase in either starvation- or staurosporine-induced and controversially, a decrease in Fas-induced apoptosis (Staurosporine is a potent inhibitor of protein kinases and activator of caspases) <xref ref-type="bibr" rid="B7">
<sup>7</sup>
</xref>. Furthermore, a decrease in the expression of CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) was described in these cells, both in the surface membrane and intracellularly <xref ref-type="bibr" rid="B8">
<sup>8</sup>
</xref>. In B cells from patients, a decrease in the <italic>in vitro</italic> production of antibodies was observed, together with an increase in apoptosis and a defect in the starvation-induced autophagy <xref ref-type="bibr" rid="B2">
<sup>2</sup>
</xref>. Taken together, these studies suggest that LRBA is important for the humoral response, immune regulation and defense against infections, both for extracellular and intracellular microorganisms, influencing the survival and homeostasis of T and B cells.</p>
</sec>
<sec>
<title>LRBA: general characteristics</title>
<p>
<italic>LRBA</italic> is located on chromosome 4q31.3 and comprises 750,839 bp along 58 exons. The protein contains 2,863 amino acids and has a molecular mass of (319 kDa (<xref ref-type="fig" rid="f1">Fig. 1</xref>). Three different transcripts of 1344, 836 and 787 bp has been detected in different mice tissues <xref ref-type="bibr" rid="B9">
<sup>9</sup>
</xref>. Additionally, the expression of the LRBA messenger RNA (mRNA) increases 2-4 times after stimulation with lipopolysaccharide (LPS) in different cell lines <xref ref-type="bibr" rid="B9">
<sup>9</sup>
</xref>.</p>
<p>
<fig id="f1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Schematic representation of LRBA and the coding protein. Human LRBA contains 750,839 bp spanning 58 exons. Its cytogenetic location is 4q31.3. The human LRBA protein comprises 2,863 amino acids and is composed of multiple domains. The predicted molecular mass is 319 kD.</title></caption><graphic xlink:href="1657-9534-cm-49-03-00236-gf1"></graphic></fig>
</p>
<p>This protein has different domains and among them, the BEACH domain (beige and Chediak-Higashi) is the most characterized. This domain, with (280 amino acids in length, is conserved in several proteins grouped overall as the BEACH domain containing proteins (BDCP) <xref ref-type="bibr" rid="B10">
<sup>10</sup>
</xref>, and is mostly located towards the C-terminal <xref ref-type="bibr" rid="B11">
<sup>11</sup>
</xref>
<sup>,</sup>
<xref ref-type="bibr" rid="B12">
<sup>12</sup>
</xref>. The function of this domain is unknown and the sequence does not show homology with any other protein in the human proteome database <xref ref-type="bibr" rid="B11">
<sup>11</sup>
</xref>
<sup>,</sup>
<xref ref-type="bibr" rid="B12">
<sup>12</sup>
</xref>. In addition to the BEACH domain, the BDCP shares the ConA-like domain (concanavalin A-like), PH (Pleckstrin homology) and WD40 (repeats of tryptophan and aspartic acid) domains. On the other hand, the domain DUF1088 (domain of unknown function 1088) is shared only by LRBA and its paralog neurobeachin, which may indicate specific functions of these two proteins not shared by other members of the BDCP.</p>
<p>In addition to these domains, LRBA seems to contain a VHS domain (VPS (vacuolar protein sorting)-27, Hrs (hepatocyte growth factor-regulated tyrosine kinase sustrate) STAM (signal transducing adaptor molecule) domain) <xref ref-type="bibr" rid="B13">
<sup>13</sup>
</xref>. </p>
<p>The possible functions of all these domains are explained in <xref ref-type="table" rid="t1">Table 1</xref>.</p>
<p>
<table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><title>General characteristics of the LRBA protein domains.</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Domain</th><th align="left" colspan="1" rowspan="1">Characteristics </th><th align="left" colspan="1" rowspan="1">Reference </th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">BEACH</td><td align="left" colspan="1" rowspan="1">It is present in proteins involved in vesicle trafficking, membrane dynamics and receptor signaling</td><td align="left" colspan="1" rowspan="1">
<xref ref-type="bibr" rid="B12">
<sup>12</sup>
</xref>
<sup>,</sup>
<xref ref-type="bibr" rid="B13">
<sup>13</sup>
</xref>
</td></tr><tr><td align="left" colspan="1" rowspan="1">PH</td><td align="left" colspan="1" rowspan="1">Interacts with phosphatidyl-inositol within biological membranes, hetero-trimeric G proteins and protein kinase C. This allows the appropriate targeting of proteins to different cellular compartments or the activation of signal transduction pathways.</td><td align="left" colspan="1" rowspan="1">
<xref ref-type="bibr" rid="B54">
<sup>54</sup>
</xref>
</td></tr><tr><td align="left" colspan="1" rowspan="1">WD40</td><td align="left" colspan="1" rowspan="1">Involved in signal transduction, cell cycle control and apoptosis. It allows transient protein-protein interaction or the assembly of protein complexes.</td><td align="left" colspan="1" rowspan="1">
<xref ref-type="bibr" rid="B55">
<sup>55</sup>
</xref>
</td></tr><tr><td align="left" colspan="1" rowspan="1">ConA-like</td><td align="left" colspan="1" rowspan="1">Participates in trafficking and classification of proteins along the secretory pathway</td><td align="left" colspan="1" rowspan="1">
<xref ref-type="bibr" rid="B56">
<sup>56</sup>
</xref>
</td></tr><tr><td align="left" colspan="1" rowspan="1">DUF1088</td><td align="left" colspan="1" rowspan="1">The function of this domain is unknown. However, a penta-arginine sequence located in the DUF1088 domain of NBEA was identified as a potential signal of nuclear localization</td><td align="left" colspan="1" rowspan="1">
<xref ref-type="bibr" rid="B57">
<sup>57</sup>
</xref>
</td></tr><tr><td align="left" colspan="1" rowspan="1">VHS</td><td align="left" colspan="1" rowspan="1">Located in the N-terminal portion of proteins associated with endocytosis and/or vesicular trafficking. It likely functions as an adapter domain that helps to locate proteins in the cell membrane or in membranes of the endocytic machinery</td><td align="left" colspan="1" rowspan="1">
<xref ref-type="bibr" rid="B13">
<sup>13</sup>
</xref>
</td></tr></tbody></table></table-wrap>
</p>
<p>With respect to tissue-specific expression, transcripts of this protein have been observed mainly bone marrow, lymph nodes, spleen, fetal liver, placenta, kidney and pancreas by RT-PCR (Reverse transcription polymerase chain reaction) and qPCR (quantitative polymerase chain reaction) <xref ref-type="bibr" rid="B2">
<sup>2</sup>
</xref>. Remarkably, the LRBA expression is not limited to the immune system, and considerably increases in several cancer tissues <xref ref-type="bibr" rid="B14">
<sup>14</sup>
</xref>. These findings suggest that LRBA function is more related to basic cellular mechanisms of growth, development and survival. At the subcellular level, using a probe directed against the LRBA BEACH domain, this protein has been observed in the cytosol, Golgi apparatus and some lysosomes in the LPS-stimulated murine macrophage cell line RAW264.7 <xref ref-type="bibr" rid="B9">
<sup>9</sup>
</xref>. In addition, with the use of the electron microscopy, LRBA is observed in endoplasmic reticulum, plasma membrane and clathrin-associated endocytic vesicles in the same cell line <xref ref-type="bibr" rid="B9">
<sup>9</sup>
</xref>.</p>
</sec>
<sec>
<title>LRBA function</title>
<sec>
<title>LRBA participates in vesicular trafficking and receptor recycling</title>
<p>CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) is a protein receptor located in the plasmatic membrane of activated T cells. It functions to regulate homeostasis and peripheral immunological tolerance through the inhibition of T cell activation, competing with the costimulatory molecule CD28 for the specific ligation of CD80 and CD86, which are expressed on the surface of antigen-presenting cells <xref ref-type="bibr" rid="B15">
<sup>15</sup>
</xref>. While CD28 resides mainly on the cell surface, CTLA-4 is located first in intracellular compartments such as Golgi apparatus, endosomes, secretory granules and lysosomes. The T cell receptor (TCR) stimulation promotes CTLA-4 trafficking from vesicular compartments to the cell membrane, however, once it is already in the membrane, this receptor is continuously endocytosed via clathrin-coated vesicles. After endocytosis, some CTLA-4 molecules are recycled to the cell membrane while others are rapidly degraded in lysosomal compartments <xref ref-type="bibr" rid="B16">
<sup>16</sup>
</xref>
<sup>,</sup>
<xref ref-type="bibr" rid="B17">
<sup>17</sup>
</xref>. CTLA-4 contains a small cytoplasmic tail with two tyrosine motifs at position Y201VKM and Y218FIP. Several intracellular proteins bind to the Y201VKM motif, including AP-1 and AP-2 (clathrin-associated adapter). AP-2 mediates the internalization of CTLA-4 from the cell surface to endosomes and lysosomal compartments whereas AP-1 regulates CTLA-4 trafficking from the Golgi apparatus to endosomal compartments and lysosomes for degradation <xref ref-type="bibr" rid="B17">
<sup>17</sup>
</xref>. In a recent study, it was demonstrated that LRBA is necessary for the vesicular trafficking of CTLA-4 towards the plasma membrane <xref ref-type="bibr" rid="B8">
<sup>8</sup>
</xref>. LRBA regulates the recycling of CTLA-4 from endosomes to the cell membrane supporting the maintenance of its intracellular levels for the immediate mobilization to the surface membrane, as this molecule is required. Thus, a deficiency of LRBA favors a rapid degradation of CTLA-4 in the lysosome compartments, with its concomitant decrease both intracellular and extracellularly <xref ref-type="bibr" rid="B8">
<sup>8</sup>
</xref>. This work also demonstrated that LRBA interacts through its ConA-like- and the PH-BEACH domains with the cytoplasmic tail of CTLA-4, specifically with the Y201VKM motif. Finally, the silencing of AP-1, but not AP-2 partially rescues the CTLA-4 loss in the LRBA deficient cells. These results suggest that LRBA blocks the trafficking of CTLA-4 to lysosomes, competing with AP-1 for binding to its specific binding motif <xref ref-type="bibr" rid="B8">
<sup>8</sup>
</xref>. Recent findings indicated that Foxp3 + CD4 + cells from LRBA-deficient mouse spleen cells also exhibit an intracellular decrease in CTLA-4 <xref ref-type="bibr" rid="B18">
<sup>18</sup>
</xref>.</p>
<p>Other study that demonstrates the LRBA role in vesicular trafficking is related to the epidermal growth factor receptor (EGFR). Dominant-negative <italic>LRBA</italic> mutants decreases the expression and phosphorylation of EGFR <xref ref-type="bibr" rid="B14">
<sup>14</sup>
</xref>. EGFR is a tyrosine kinase receptor that is expressed in a wide variety of tissues, interacting not only with EGF but also with TGF-β (Transforming growth factor-β), and other ligands. This induces the dimerization and trans-auto-phosphorylation of the receptor by recruiting proteins that activate signaling pathways necessary for the proliferation, differentiation, cell growth, migration and inhibition of apoptosis <xref ref-type="bibr" rid="B19">
<sup>19</sup>
</xref>. Similar to CTLA-4 in lymphocytes, the EGFR expression on the cell surface is regulated by clathrin-mediated endocytosis, which leads either to its degradation via the lysosome compartment or its recycling to the cell surface <xref ref-type="bibr" rid="B20">
<sup>20</sup>
</xref>
<sup>,</sup>
<xref ref-type="bibr" rid="B21">
<sup>21</sup>
</xref>. Defects in the vesicular trafficking of this receptor result in an aberrant localization, which enhances signaling, allowing the development of cancer <xref ref-type="bibr" rid="B22">
<sup>22</sup>
</xref>. Although it is still not known if LRBA and EGFR interact physically, it has been demonstrated that AP-2 facilitates endocytosis and trafficking of EGFR by the endocytic route <xref ref-type="bibr" rid="B3">
<sup>3</sup>
</xref>
<sup>.</sup>
</p>
<p>Finally, LRBA deficient patients exhibited a decrease in apoptosis mediated by the death receptor Fas, as compared to healthy donors <xref ref-type="bibr" rid="B6">
<sup>6</sup>
</xref>. Fas receptor promotes apoptosis through the extrinsic pathway, after binding to Fas ligand (FasL). After this binding, a process of FasL internalization occur, similar to EGFR, which is crucial to trigger apoptosis <xref ref-type="bibr" rid="B24">
<sup>24</sup>
</xref>. To date, it is unknown whether LRBA-deficient patients exhibit alterations in the amount of FasL in the plasmatic membrane, but the increase in serum FasL in these patients could suggest that the LRBA deficiency may have an effect on FasL, similar to CTLA-4, regulating its trafficking either towards plasmatic membrane or lysosomes <xref ref-type="bibr" rid="B25">
<sup>25</sup>
</xref>. </p>
<p>These evidences suggest that LRBA might be involved in the vesicular trafficking of other receptors in lymphocytes. In LRBA deficient mice, defects have been reported in the phosphorylation of ERK1/2 (extracellular signal-regulated kinases) and AKT in natural killer (NK) cells stimulated with anti-NKG2D or anti-NKp46 antibodies, with a significant decrease in the production of IFN-gamma by these cells after stimulation <xref ref-type="bibr" rid="B26">
<sup>26</sup>
</xref>. Although this study did not determine the expression levels of these receptors in LRBA-deficient mice, there is some evidence that the exposure to specific ligands induces the degradation of NKG2D and DAP10, the intracellular adapter molecule of this receptor in lysosomes <xref ref-type="bibr" rid="B27">
<sup>27</sup>
</xref>. This regulation might be mediated by clathrin <xref ref-type="bibr" rid="B28">
<sup>28</sup>
</xref>. It is not known if LRBA is involved in the intracellular trafficking of these receptors in NK cells. Likewise, considering that the LRBA deficiency leads to defects in antibody responses, it would be also important to consider whether this molecule modulates the expression and function of other receptors whose expression is modulated by vesicular compartments, especially in regard to B cells activation <xref ref-type="bibr" rid="B29">
<sup>29</sup>
</xref>.</p>
<p>Despite these studies on the LRBA-mediated modulation of some cellular receptors, little is known about the intracellular pathways that this molecule employ to perform this function. This transport seems to be carried out by the recruitment of proteins in clathrin-coated vesicles, on which the receptors are removed to early endosomes and subsequently degraded by lysosomal enzymes or recycled to the cell surface <xref ref-type="bibr" rid="B30">
<sup>30</sup>
</xref>. AP-1 is considered necessary for this trafficking. The location of AP-1 in the Golgi apparatus and endosomes depends on its direct binding to Arf (ADP-ribosylation factor) -1 and specifically in recycling endosomes, to Arf-6, among other protein complexes <xref ref-type="bibr" rid="B31">
<sup>31</sup>
</xref>. As already mentioned, LRBA inhibits the degradation of CTLA-4 in lysosomes by competition with AP-1, which suggest that this protein is necessary for mobilization to these compartments <xref ref-type="bibr" rid="B8">
<sup>8</sup>
</xref>. However, the relationship of LRBA with the endosomal pathway is unclear. The recycling of receptors also depends on vesicular compartments, and the proteins this required, namely, Arf, enzymes such as phospholipase D and Rab proteins. Interestingly, a study conducted in <italic>Drosophila</italic> suggests a possible functional interaction between bchs (blue cheese), a member of the BEACH family, and Rab11 <xref ref-type="bibr" rid="B32">
<sup>32</sup>
</xref>. These findings suggest that, as well as Rab11, Bchs could be involved in the regulation of vesicle trafficking.</p>
<p>Therefore, studies quantifying the expression of the mentioned receptors in LRBA deficient cells (either by silencing or from patients) are needed. It would also be useful to use advanced microscopy techniques to investigate the location of LRBA in other organelles involved in this type of trafficking. In addition, studies of co-immunoprecipitation between LRBA and vesicular trafficking proteins, the use of drugs that block this trafficking or the implementation of negative dominant ARFs, phospholipase D or Rab, could expand our knowledge about the interaction of LRBA with other vesicular trafficking molecules and thus determine its relationship with the membrane expression of receptors such as EGFR, Fas or the activating receptors of NK cells, B cells or others in immune cells. </p>
</sec>
<sec>
<title>LRBA is a molecule involved in autophagy</title>
<p>Autophagy is a mechanism of lysosomal degradation by which the cell destroys damaged organelles and microorganisms and helps to recycle macromolecules. In this process, a double membrane of isolation or phagophore is formed near to the target, which is then elongated, surrounding it, to later mature with the assimilation of a cytosolic charge forming the autophagosome. For the maturation to be effective, the autophagosome must be fused with early or late endosomes forming a structure called amphisome <xref ref-type="bibr" rid="B33">
<sup>33</sup>
</xref>
<sup>,</sup>
<xref ref-type="bibr" rid="B34">
<sup>34</sup>
</xref>. Finally, the mature autophagosomes fuses with lysosomes to proceed with the degradation of its content by lysosomal proteases and hydrolytic enzymes <xref ref-type="bibr" rid="B35">
<sup>35</sup>
</xref>. </p>
<p>Several of the genes homologous to LRBA are involved in autophagy. WDFY3 (WD and FYVE zinc finger domain containing protein 3) encodes a protein that colocalizes with autophagosome markers <xref ref-type="bibr" rid="B36">
<sup>36</sup>
</xref>
<sup>,</sup>
<xref ref-type="bibr" rid="B37">
<sup>37</sup>
</xref>. In addition, the PH-BEACH domain interacts with the p62 protein <xref ref-type="bibr" rid="B34">
<sup>34</sup>
</xref>. P62 is a protein located in the autophagosome formation sites and is associated with both LC3 (microtubule-associated protein 1A / 1B-light chain 3) and ubiquitinated proteins <xref ref-type="bibr" rid="B34">
<sup>34</sup>
</xref>
<sup>,</sup>
<xref ref-type="bibr" rid="B38">
<sup>38</sup>
</xref>
<sup>,</sup>
<xref ref-type="bibr" rid="B39">
<sup>39</sup>
</xref>. LC3 is a cytosolic protein that when conjugated with a phosphatidylethanolamine is recruited to the autophagosome membrane favoring the autophagic influx <xref ref-type="bibr" rid="B34">
<sup>34</sup>
</xref>. On the other hand, defects in the gene <italic>mauve</italic> (mv) in <italic>Drosophila</italic>, which is ortholog of <italic>LYST</italic>, affect the autophagosome function <xref ref-type="bibr" rid="B40">
<sup>40</sup>
</xref>.</p>
<p>In immortalized B cells from patients with LRBA deficiency, a significant reduction in the autophagy influx in response to starvation, together with an increase in the Golgi apparatus area, accumulation of autophagosomes and the presence of centrioles is observed, in comparison with those cells from healthy individual <xref ref-type="bibr" rid="B2">
<sup>2</sup>
</xref>. These results suggest that the autophagy influx is impaired in the LRBA deficiency, a finding that was demonstrated by a deficient fusion of autophagosome to lysosomes in immortalized B cells from LRBA-deficient patients subjected to starvation <xref ref-type="bibr" rid="B2">
<sup>2</sup>
</xref>. However, what are the possible functions of LRBA in the autophagy influx? Considering that both, the cell surface receptor trafficking and autophagy need endocytic vesicles, and that LRBA is likely located in these vesicles, a possible hypothesis would be that LRBA facilitates fusion between autophagosomes and the late endosomes, and therefore, the formation of the amphisome. One of the markers of late endosomes is Rab7 and this molecule is required for the formation of amphisomas in CHO cells transfected with the dominant negative mutant of Rab7, T22N <xref ref-type="bibr" rid="B33">
<sup>33</sup>
</xref>. Another hypothesis is that, in the same manner as the CTLA-4 vesicular trafficking, also in the context of autophagy in lymphocytes, LRBA would compete with clathrin adapter proteins, regulating this process. This since molecules such as clathrin and its adapter proteins are also important for the autophagic influx <xref ref-type="bibr" rid="B40">
<sup>40</sup>
</xref>
<sup>-</sup>
<xref ref-type="bibr" rid="B42">
<sup>42</sup>
</xref>. On the other hand, <italic>in silico</italic> tools have predicted that LRBA interacts with LC3 <xref ref-type="bibr" rid="B13">
<sup>13</sup>
</xref>. </p>
<p>In an attempt to associate the defects in autophagy with the clinical characteristics found in LRBA deficiency individuals, it is important to bear in mind that one of the most common clinical manifestations among these individuals is the gastropathy, phenotypically expressed in many cases as Inflammatory Disease Intestinal (IBD) or IBD-like disease, a condition characterized by recurrent destructive inflammation in the intestinal tract <xref ref-type="bibr" rid="B3">
<sup>3</sup>
</xref>
<sup>-</sup>
<xref ref-type="bibr" rid="B5">
<sup>5</sup>
</xref>
<sup>).</sup> An increase in the production of IL-1β in the interstitial mucosa has been implicated with uncontrolled inflammation in the course of this disease <xref ref-type="bibr" rid="B43">
<sup>43</sup>
</xref>. Macrophages derived from <italic>ATG16L1</italic> (autophagy-related 16-like 1)-knockout mice present with a defect in autophagy and exhibit a high production of IL-1β after LPS stimulation <xref ref-type="bibr" rid="B44">
<sup>44</sup>
</xref>. Likewise, the polymorphism rs2241880 in <italic>ATG16L1</italic> increased the production of IL-1β in peripheral blood mononuclear cells isolated from patients with IBD <xref ref-type="bibr" rid="B45">
<sup>45</sup>
</xref>. Autophagy can regulate the production of IL-1β through two pathways: in the absence of autophagy, defective mitochondria accumulate generating an increase in ROS (reactivating oxygen species) and releasing mitochondrial DNA into the cytoplasm, events that further activate the inflammosome, increasing the production of IL-1β <xref ref-type="bibr" rid="B46">
<sup>46</sup>
</xref>
<sup>,</sup>
<xref ref-type="bibr" rid="B47">
<sup>47</sup>
</xref>. On the other hand, the degradation of pro-IL-1β mediated by autophagy processes limits the substrate available for the inflammasome, thus regulating the activation of IL-1β <xref ref-type="bibr" rid="B48">
<sup>48</sup>
</xref>
<sup>,</sup>
<xref ref-type="bibr" rid="B49">
<sup>49</sup>
</xref>. Therefore, alterations in autophagy would impair this mechanism, increasing the levels of IL-1β and inducing inflammation. It is not known if the intestinal manifestations in LRBA deficient patients are mediated by an excessive activity of the inflammosome and exaggerated production of IL-1β.</p>
<p>Microscopy studies with LRBA deficient cells are required to study the intracellular distribution of molecules such as Rab7 and LC3 after the autophagic influx. It would also be interesting to investigate if LRBA interacts physically with any of the Rab molecules involved in the different types of autophagy, by means of co-immunoprecipitation assays. The role of LRBA in inflamosome activity could be addressed by measuring the production of IL-1β in LRBA deficient phagocytic or intestinal epithelial cells or by determining the activity of active auto-inflammosome by means of redistribution of ASC (apoptosis-associated speck-like protein containing a caspase-recruitment domain), which is a protein that recruits the necessary caspases for the activation of the inflammosome. </p>
</sec>
<sec>
<title>LRBA participates in apoptosis.</title>
<p>In LRBA deficient patients’ immortalized B cells subjected to starvation, a significant increase in apoptosis is observed <xref ref-type="bibr" rid="B2">
<sup>2</sup>
</xref>. Additionally, in <italic>LRBA-</italic>knockdown HeLa cells exposed to ultraviolet light or staurosporine, a greater cleavage of PARP (Poly (ADP-ribose) polymerase) and caspase 3 are observed, events that are necessary to initiate the cascade of signaling that eventually leads to apoptosis <xref ref-type="bibr" rid="B14">
<sup>14</sup>
</xref>. </p>
<p>Apoptosis is a type of programmed cell death to control development and growth. For long time, caspases have been considered as the proteases involved in the execution of the apoptosis program, and nowadays it is known that the partial destabilization of the lysosomal membrane, with the consequent release of hydrolytic enzymes, can initiate and execute apoptosis, byactivating caspases <xref ref-type="bibr" rid="B50">
<sup>50</sup>
</xref>
<sup>,</sup>
<xref ref-type="bibr" rid="B51">
<sup>51</sup>
</xref>. In germinal centers derived from tonsils, it is observed that B cell lysosomal destabilization contributes to apoptosis <xref ref-type="bibr" rid="B50">
<sup>50</sup>
</xref>. The induction of lysosomal damage in these cells resulted in the cleavage of caspase 8 and also of DNA, due to the increased activity of cathepsin B in the cytoplasm. Interestingly, it has been observed that p53 induces lysosomal destabilization <xref ref-type="bibr" rid="B52">
<sup>52</sup>
</xref> and the LRBA promoter is negatively regulated by p53 <xref ref-type="bibr" rid="B14">
<sup>14</sup>
</xref>. p53 is a tumor suppressor gene that encodes a nuclear transcription factor, whose expression increases in response to damage, blocking the cell cycle either to facilitate DNA repair or to induce apoptosis <xref ref-type="bibr" rid="B52">
<sup>52</sup>
</xref>. It is possible to hypothesize that, p53 would induce lysosomal destabilization in the absence of LRBA, and therefore, trigger apoptosis in lymphocytes. However, the mechanism by which p53 induces lysosomal destabilization or how LRBA protects cells from apoptosis is up to date unknown.</p>
<p>However, a complex crosstalk between autophagy and apoptosis exists, that is critical for cell fate. Under certain cellular conditions, autophagy can promote cell survival and prevent apoptosis <xref ref-type="bibr" rid="B53">
<sup>53</sup>
</xref>. For example, increased autophagy in cells deprived of nutrients or growth factors allows cell survival by inhibiting apoptosis. A suggested mechanism by which autophagy inhibits apoptosis is the sequestration of mitochondria damaged by the autophagosome, thus preventing the released mitochondrial cytochrome c to form a functional apoptosome in the cytoplasm <xref ref-type="bibr" rid="B53">
<sup>53</sup>
</xref>
<sup>.</sup> However, in other conditions, autophagy may culminate in cell death, dependently or independently of apoptosis <xref ref-type="bibr" rid="B53">
<sup>53</sup>
</xref>. Additionally, there are several proteins that share a dual role in both apoptosis and autophagy <xref ref-type="bibr" rid="B53">
<sup>53</sup>
</xref>. These autophagic proteins positively or negatively regulate mitochondrial apoptosis directly or indirectly through the cleavage of proteases <xref ref-type="bibr" rid="B54">
<sup>54</sup>
</xref>. In the context of LRBA deficient cells, defective autophagy together with an increase in apoptosis has been demonstrated. It is not known if either alterations in the clearance of damaged mitochondria or an exaggerated cleavage of proteases are responsible for this cellular phenotype.</p>
<p>Therefore, it is necessary to evaluate the quantity and integrity of the lysosomes in LRBA deficient immune cells. In addition, the kinetics of lysosomal destabilization could be estimated in relation to the kinetics of other apoptotic parameters such as mitochondrial instability, caspase-3 activation and DNA cleavage.</p>
</sec>
</sec>
<sec sec-type="conclusions">
<title>Conclusion</title>
<p>In the last decade, a great amount of new information has been generated about the association of LRBA with the immune system, its cellular localization and function. This has improve our understanding about their role in processes such as vesicular trafficking, autophagy and apoptosis. However, many questions remain to be answered. First, is LRBA located in the endomembrane system? Does LRBA form protein complexes with either Rab or Arf? Does LRBA modulate the traffic of receptors such as Fas, NKG2D or NKp46? There is evidence that LRBA prevents the degradation of CTLA-4 by competing AP-1 in human regulatory T lymphocytes, a protein that interacts with Arf1 and Arf6. In addition, the Bchs ortholog gene in <italic>Drosophila</italic> leads to Rab11-dependent vesicular trafficking. This raises the possibility that LRBA modulates several immune receptors by vesicle trafficking and, therefore, it is determinant in the normal development of the immune response.</p>
<p>Secondly, although defects in LRBA lead to poor autophagy, what are the functions of this protein in these cell mechanism? What is its localization in autophagosome, amphisomes and autophagolysomomes? Does LRBA interact physically with autophagy-related molecules such as LC3, ATG or Rab7?, By studying vesicular trafficking and autophagy, we found a possible connection mediated by Rab7, which is needed for the fusion between late endosomes and the autophagolysosome, which might suggest that LRBA is required for the fusion between these two organelles.</p>
<p>Third, can LRBA deficiency affect lysosomal stability and thereby trigger apoptosis? The interaction of LRBA with lysosomes has been described, however, the mechanism underlying its function in lysosomes have not yet been fully elucidated.</p>
<p>Finally, the association between endosomal trafficking, autophagy, apoptosis in the context of the LRBA function have not yet been addressed. We propose a model for the function of LRBA in the CTLA-4 trafficking (<xref ref-type="fig" rid="f2">Fig. 2</xref>). A complete understanding of the LRBA function also requires a detailed dissection of its structure. It is necessary to characterize the function of their domains and its interaction with other proteins in cellular homeostasis.</p>
<p>
<fig id="f2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>LRBA in the regulation of vesicular trafficking. CTLA-4 is a receptor located in the membrane of activated T lymphocytes. This receptor is internalized in clathrin-coated vesicles by its interaction with AP2. LRBA regulates the recycling of CTLA-4 from endosomes to the cell membrane, preventing its degradation in the lysosomal compartments. The appropriate autophagy influx also need the endocytic vesicles. LRBA is located in these vesicles and might interact with molecules not yet identified to facilitate fusion between the autophagosomes and the late endosomes.</title></caption><graphic xlink:href="1657-9534-cm-49-03-00236-gf2"></graphic></fig>
</p>
<p>New technologies of advanced microscopy, genetic editing such as CRISPR / Cas9 system or next-generation genomics tools, in the context of transcriptomes, proteomes, metabolomes and epigenomes would help to solve many of these questions to clarify the role of this protein and raise strategies for its regulation.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure" id="fn1">
<p><bold>Funding:</bold> This review was supported by the Instituto Colombiano para el Desarrollo de la Ciencia y Tecnología, COLCIENCIAS (Grant# 1115-569-34430), and Catalina Martínez Jaramillo is sponsored by the Science and Technology grant, COLCIENCIAS 727</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Picard</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Al-Herz</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Bousfiha</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Casanova</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Chatila</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Conley</surname>
<given-names>ME</given-names>
</name>
</person-group>
<article-title>Primary immunodeficiency diseases an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015</article-title>
<source/>J Clin Immunol
          <year>2015</year>
<volume>35</volume>
<fpage>696</fpage>
<lpage>726</lpage>
<pub-id pub-id-type="pmid">26482257</pub-id>
</element-citation>
</ref>
<ref id="B2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopez-Herrera</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tampella</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Pan-Hammarström</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Herholz</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Trujillo-Vargas</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Phadwal</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity</article-title>
<source/>Am J Hum Genet
          <year>2012</year>
<volume>90</volume>
<fpage>986</fpage>
<lpage>1001</lpage>
<pub-id pub-id-type="pmid">22608502</pub-id>
</element-citation>
</ref>
<ref id="B3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gamez-Días</surname>
<given-names>L</given-names>
</name>
<name>
<surname>August</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Stepensky</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Revel-Vilk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Seidel</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Noriko</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency</article-title>
<source/>J Allergy Clin Immunol
          <year>2016</year>
<volume>137</volume>
<fpage>223</fpage>
<lpage>230</lpage>
<pub-id pub-id-type="pmid">26768763</pub-id>
</element-citation>
</ref>
<ref id="B4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lo</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Fritz</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Uzel</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Jordan</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Lenardo</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Blood spotlight CHAI and LATAIE new genetic diseases of CTLA-4 checkpoint insufficiency</article-title>
<source/>Blood
          <year>2016</year>
<volume>128</volume>
<fpage>1</fpage>
<lpage>3</lpage>
<pub-id pub-id-type="pmid">27389536</pub-id>
</element-citation>
</ref>
<ref id="B5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alkhairy</surname>
<given-names>OK</given-names>
</name>
<name>
<surname>Abolhassani</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rezaei</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Andersen</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Chavoshzadeh</surname>
<given-names>ZM</given-names>
</name>
</person-group>
<article-title>Spectrum of phenotypes associated with mutations in LRBA</article-title>
<source/>J Clin Immunol
          <year>2015</year>
<volume>36</volume>
<fpage>33</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="pmid">26707784</pub-id>
</element-citation>
</ref>
<ref id="B6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Revel-Vilk</surname>
<given-names>FU</given-names>
</name>
<name>
<surname>Keller</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Nabhani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gámez-Díaz</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rensing-Ehl</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Autoimmune lymphoproliferative syndrome-like disease in patients with LRBA mutation</article-title>
<source/>Clin Immunol
          <year>2015</year>
<volume>159</volume>
<fpage>84</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="pmid">25931386</pub-id>
</element-citation>
</ref>
<ref id="B7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Serwas</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Kansu</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Santos-Valente</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kuloglu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Demir</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yaman</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Atypical manifestation of LRBA deficiency with predominant IBD-like phenotype</article-title>
<source/>Inflamm Bowel Dis
          <year>2015</year>
<volume>21</volume>
<fpage>40</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="pmid">25479458</pub-id>
</element-citation>
</ref>
<ref id="B8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lo</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Kanellopoulou</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy</article-title>
<source/>Science
          <year>2015</year>
<volume>349</volume>
<fpage>436</fpage>
<lpage>440</lpage>
<pub-id pub-id-type="pmid">26206937</pub-id>
</element-citation>
</ref>
<ref id="B9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Howson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Haller</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kerr</surname>
<given-names>WG</given-names>
</name>
</person-group>
<article-title>Identification of a novel lipopolysaccharide-inducible gene with key features of both A kinase anchor proteins and chs1/beige proteins</article-title>
<source/>J Immunol
          <year>2001</year>
<volume>166</volume>
<fpage>4586</fpage>
<lpage>4595</lpage>
<pub-id pub-id-type="pmid">11254716</pub-id>
</element-citation>
</ref>
<ref id="B10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cullinane</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Schäffer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Huizing</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The BEACH Is Hot A LYST of emerging roles for BEACH-domain containing proteins in human disease</article-title>
<source/>Traffic
          <year>2013</year>
<volume>14</volume>
<fpage>749</fpage>
<lpage>766</lpage>
<pub-id pub-id-type="pmid">23521701</pub-id>
</element-citation>
</ref>
<ref id="B11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gebauer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jogl</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Myszka</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Crystal structure of the PH-BEACH domains of human LRBA/BGL</article-title>
<source/>Biochemistry
          <year>2004</year>
<volume>43</volume>
<fpage>14873</fpage>
<lpage>14880</lpage>
<pub-id pub-id-type="pmid">15554694</pub-id>
</element-citation>
</ref>
<ref id="B12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jogl</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gerwald</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Gebauer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wiegmann</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Crystal structure of the BEACH domain reveals an unusual fold and extensive association with a novel PH domain</article-title>
<source/>EMBO J
          <year>2002</year>
<volume>21</volume>
<fpage>4785</fpage>
<lpage>4795</lpage>
<pub-id pub-id-type="pmid">12234919</pub-id>
</element-citation>
</ref>
<ref id="B13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J-W</given-names>
</name>
<name>
<surname>Lockey</surname>
<given-names>RF</given-names>
</name>
</person-group>
<article-title>Lipopolysaccharide-responsive beige-like anchor (LRBA), a novel regulator of human immune disorders</article-title>
<source/>Austin J Clin Immunol
          <year>2014</year>
<volume>1</volume>
<fpage>1004</fpage>
<lpage>1004</lpage>
</element-citation>
</ref>
<ref id="B14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Gamsby</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Highfill</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Mora</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Bloom</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Yeatman</surname>
<given-names>TJ</given-names>
</name>
</person-group>
<article-title>Deregulated expression of LRBA facilitates cancer cell growth</article-title>
<source/>Oncogene
          <year>2004</year>
<volume>23</volume>
<fpage>4089</fpage>
<lpage>4097</lpage>
<pub-id pub-id-type="pmid">15064745</pub-id>
</element-citation>
</ref>
<ref id="B15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCoy</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Le Gros</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>The role of CTLA-4 in the regulation of T cell immune responses</article-title>
<source/>Immunol Cell Biol
          <year>1999</year>
<volume>77</volume>
<fpage>1</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="pmid">10101680</pub-id>
</element-citation>
</ref>
<ref id="B16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walker</surname>
<given-names>LSK</given-names>
</name>
<name>
<surname>Sansom</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses</article-title>
<source/>Nat Rev Immunol
          <year>2011</year>
<volume>11</volume>
<fpage>852</fpage>
<lpage>863</lpage>
<pub-id pub-id-type="pmid">22116087</pub-id>
</element-citation>
</ref>
<ref id="B17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valk</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rudd</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>CTLA-4 trafficking and surface expression</article-title>
<source/>Trends Immunol
          <year>2008</year>
<volume>29</volume>
<fpage>272</fpage>
<lpage>279</lpage>
<pub-id pub-id-type="pmid">18468488</pub-id>
</element-citation>
</ref>
<ref id="B18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gamez-Diaz</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jäger</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Proietti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Felber</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Soulas-Sprauel</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Immunological phenotype of the murine Lrba knockout</article-title>
<source/>Immunol Cell Biol
          <year>2017</year>
<volume>9</volume>
<fpage>789</fpage>
<lpage>802</lpage>
</element-citation>
</ref>
<ref id="B19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wee</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Epidermal Growth Factor Receptor Cell Proliferation</article-title>
<source/>Cancers (Basel)
          <year>2017</year>
<volume>9</volume>
<elocation-id>E52</elocation-id>
<pub-id pub-id-type="pmid">28513565</pub-id>
</element-citation>
</ref>
<ref id="B20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sigismund</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Argenzio</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tosoni</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cavallaro</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Polo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Di Fiore</surname>
<given-names>PP</given-names>
</name>
</person-group>
<article-title>Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation</article-title>
<source/>Dev Cell
          <year>2008</year>
<volume>15</volume>
<fpage>209</fpage>
<lpage>219</lpage>
<pub-id pub-id-type="pmid">18694561</pub-id>
</element-citation>
</ref>
<ref id="B21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sorkin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Goh</surname>
<given-names>LK</given-names>
</name>
</person-group>
<article-title>Endocytosis and intracellular trafficking of ErbBs</article-title>
<source/>Exp Cell Res
          <year>2008</year>
<volume>315</volume>
<fpage>683</fpage>
<lpage>696</lpage>
</element-citation>
</ref>
<ref id="B22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goh</surname>
<given-names>LK</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Gygi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sorkin</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Multiple mechanisms collectively regulate clathrin-mediated endocytosis of the epidermal growth factor receptor</article-title>
<source/>J Cell Biol
          <year>2010</year>
<volume>189</volume>
<fpage>871</fpage>
<lpage>883</lpage>
<pub-id pub-id-type="pmid">20513767</pub-id>
</element-citation>
</ref>
<ref id="B23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rappoport</surname>
<given-names>JZ</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Endocytic trafficking of activated EGFR is AP-2 dependent and occurs through preformed clathrin spots</article-title>
<source/>J Cell Sci
          <year>2009</year>
<volume>122</volume>
<fpage>1301</fpage>
<lpage>1305</lpage>
<pub-id pub-id-type="pmid">19351721</pub-id>
</element-citation>
</ref>
<ref id="B24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Degli</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Tour</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ouasti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ivanova</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Matarrese</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Malorni</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Fas death receptor enhances endocytic membrane traffic converging into the Golgi region</article-title>
<source/>Mol Biol Cell
          <year>2009</year>
<volume>20</volume>
<fpage>600</fpage>
<lpage>615</lpage>
<pub-id pub-id-type="pmid">19037097</pub-id>
</element-citation>
</ref>
<ref id="B25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Feig</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tchikov</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Schickel</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hallas</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schütze</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>The role of receptor internalization in CD95 signaling</article-title>
<source/>EMBO J
          <year>2006</year>
<volume>25</volume>
<fpage>1009</fpage>
<lpage>1023</lpage>
<pub-id pub-id-type="pmid">16498403</pub-id>
</element-citation>
</ref>
<ref id="B26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>MY</given-names>
</name>
<name>
<surname>Sudan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Srivastava</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Neelam</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Youngs</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>LRBA is essential for allogeneic responses in bone marrow transplantation</article-title>
<source/>Sci Rep
          <year>2016</year>
<volume>6</volume>
<fpage>36568</fpage>
<lpage>36568</lpage>
<pub-id pub-id-type="pmid">27824136</pub-id>
</element-citation>
</ref>
<ref id="B27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roda-Navarro</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Reyburn</surname>
<given-names>HT</given-names>
</name>
</person-group>
<article-title>The traffic of the NKG2D / Dap10 receptor complex during Natural Killer ( NK ) cell activation</article-title>
<source/>J Biol Chem
          <year>2009</year>
<volume>284</volume>
<fpage>16463</fpage>
<lpage>16472</lpage>
<pub-id pub-id-type="pmid">19329438</pub-id>
</element-citation>
</ref>
<ref id="B28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogasawara</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hamerman</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Hsin</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Chikuma</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bour-Jordan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Impairment of NK cell function by NKG2D modulation in NOD mice</article-title>
<source/>Immunity
          <year>2003</year>
<volume>18</volume>
<fpage>41</fpage>
<lpage>51</lpage>
<pub-id pub-id-type="pmid">12530974</pub-id>
</element-citation>
</ref>
<ref id="B29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Engelke</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pirkuliyeva</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kühn</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Boyken</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Herrmann</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Macromolecular assembly of the adaptor SLP-65 at intracellular vesicles in resting B cells</article-title>
<source/>Sci Signal
          <year>2014</year>
<volume>7</volume>
<fpage>ra79</fpage>
<lpage>ra79</lpage>
<pub-id pub-id-type="pmid">25140054</pub-id>
</element-citation>
</ref>
<ref id="B30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henriksen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Grandal</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Knudsen</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>van Deurs</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Grøvdal</surname>
<given-names>LM</given-names>
</name>
</person-group>
<article-title>Internalization mechanisms of the epidermal growth factor receptor after activation with different ligands</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>8</volume>
<issue>3</issue>
<elocation-id>e58148</elocation-id>
<pub-id pub-id-type="pmid">23472148</pub-id>
</element-citation>
</ref>
<ref id="B31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shteyn</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Pigati</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fölsch</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Arf6 regulates AP-1B-dependent sorting in polarized epithelial cells</article-title>
<source/>J Cell Biol
          <year>2011</year>
<volume>194</volume>
<fpage>873</fpage>
<lpage>887</lpage>
<pub-id pub-id-type="pmid">21911479</pub-id>
</element-citation>
</ref>
<ref id="B32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khodosh</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Augsburger</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schwarz</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Garrity</surname>
<given-names>PA</given-names>
</name>
</person-group>
<article-title>Bchs, a BEACH domain protein, antagonizes Rab11 in synapse morphogenesis and other developmental events</article-title>
<source/>Development
          <year>2006</year>
<volume>133</volume>
<fpage>4655</fpage>
<lpage>4665</lpage>
<pub-id pub-id-type="pmid">17079274</pub-id>
</element-citation>
</ref>
<ref id="B33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gutierrez</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Munafó</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Berón</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Colombo</surname>
<given-names>MI</given-names>
</name>
</person-group>
<article-title>Rab7 is required for the normal progression of the autophagic pathway in mammalian cells</article-title>
<source/>J Cell Sci
          <year>2004</year>
<volume>117</volume>
<fpage>2687</fpage>
<lpage>2697</lpage>
<pub-id pub-id-type="pmid">15138286</pub-id>
</element-citation>
</ref>
<ref id="B34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hansen</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Johansen</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Following autophagy step by step</article-title>
<source/>BMC Biol
          <year>2011</year>
<volume>9</volume>
<fpage>1</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="pmid">21214944</pub-id>
</element-citation>
</ref>
<ref id="B35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ryter</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Mizumura</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>AMK</given-names>
</name>
</person-group>
<article-title>The impact of autophagy on cell death modalities</article-title>
<source/>Int J Cell Biol
          <year>2014</year>
<volume>2014</volume>
<fpage>502676</fpage>
<lpage>502676</lpage>
<pub-id pub-id-type="pmid">24639873</pub-id>
</element-citation>
</ref>
<ref id="B36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simonsen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Birkeland</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Gillooly</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Mizushima</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kuma</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yoshimori</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Alfy, a novel FYVE-domain-containing protein associated with protein granules and autophagic membranes</article-title>
<source/>J Cell Sci
          <year>2004</year>
<volume>117</volume>
<fpage>4239</fpage>
<lpage>4251</lpage>
<pub-id pub-id-type="pmid">15292400</pub-id>
</element-citation>
</ref>
<ref id="B37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Filimonenko</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Isakson</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Finley</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Melia</surname>
<given-names>TJ</given-names>
</name>
</person-group>
<article-title>The selective macroautophagic degradation of aggregated proteins requires the PI3P-binding protein Alfy</article-title>
<source/>Mol Cell
          <year>2010</year>
<volume>38</volume>
<fpage>265</fpage>
<lpage>279</lpage>
<pub-id pub-id-type="pmid">20417604</pub-id>
</element-citation>
</ref>
<ref id="B38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clausen</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Lamark</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Isakson</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Finley</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Larsen</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Brech</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>p62/SQSTM1 and ALFY interact to facilitate the formation of p62 bodies/ALIS and their degradation by autophagy</article-title>
<source/>Autophagy
          <year>2010</year>
<volume>6</volume>
<fpage>330</fpage>
<lpage>344</lpage>
<pub-id pub-id-type="pmid">20168092</pub-id>
</element-citation>
</ref>
<ref id="B39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ichimura</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Waguri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sou</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Kageyama</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hasegawa</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ishimura</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy</article-title>
<source/>Mol Cell
          <year>2013</year>
<volume>51</volume>
<fpage>618</fpage>
<lpage>631</lpage>
<pub-id pub-id-type="pmid">24011591</pub-id>
</element-citation>
</ref>
<ref id="B40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rahman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Haberman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tracy</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ray</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Krämer</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Drosophila mauve mutants reveal a role of LYST homologs late in the maturation of phagosomes and autophagosomes</article-title>
<source/>Traffic
          <year>2012</year>
<volume>13</volume>
<fpage>1680</fpage>
<lpage>1692</lpage>
<pub-id pub-id-type="pmid">22934826</pub-id>
</element-citation>
</ref>
<ref id="B41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ravikumar</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Moreau</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jahreiss</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Puri</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rubinsztein</surname>
<given-names>DC</given-names>
</name>
</person-group>
<article-title>Plasma membrane contributes to the formation of pre-autophagosomal structures</article-title>
<source/>Nat Cell Biol
          <year>2010</year>
<volume>12</volume>
<fpage>747</fpage>
<lpage>757</lpage>
<pub-id pub-id-type="pmid">20639872</pub-id>
</element-citation>
</ref>
<ref id="B42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Popovic</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dikic</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>TBC 1D5 and the AP2 complex regulate ATG9 trafficking and initiation of autophagy</article-title>
<source/>EMBO Rep
          <year>2014</year>
<volume>15</volume>
<fpage>392</fpage>
<lpage>401</lpage>
<pub-id pub-id-type="pmid">24603492</pub-id>
</element-citation>
</ref>
<ref id="B43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coccia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>OJ</given-names>
</name>
<name>
<surname>Schiering</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Asquith</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Becher</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Powrie</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>IL-1ß mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4+ Th17 cells</article-title>
<source/>J Exp Med
          <year>2012</year>
<volume>209</volume>
<fpage>1595</fpage>
<lpage>1609</lpage>
<pub-id pub-id-type="pmid">22891275</pub-id>
</element-citation>
</ref>
<ref id="B44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saitoh</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fujita</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Uematsu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Satoh</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1 beta production</article-title>
<source/>Nature
          <year>2008</year>
<volume>456</volume>
<fpage>264</fpage>
<lpage>268</lpage>
<pub-id pub-id-type="pmid">18849965</pub-id>
</element-citation>
</ref>
<ref id="B45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plantinga</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Joosten</surname>
<given-names>LAB</given-names>
</name>
<name>
<surname>Netea</surname>
<given-names>MG</given-names>
</name>
</person-group>
<article-title>ATG16L1 polymorphisms are associated with NOD2-induced hyperinflammation</article-title>
<source/>Autophagy
          <year>2011</year>
<volume>7</volume>
<fpage>1074</fpage>
<lpage>1075</lpage>
<pub-id pub-id-type="pmid">21673517</pub-id>
</element-citation>
</ref>
<ref id="B46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Yazdi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Menu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Tschopp</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>A role for mitochondria in NLRP3 inflammasome activation</article-title>
<source/>Nature
          <year>2011</year>
<volume>469</volume>
<fpage>221</fpage>
<lpage>225</lpage>
<pub-id pub-id-type="pmid">21124315</pub-id>
</element-citation>
</ref>
<ref id="B47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakahira</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Haspel</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Rathinam</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Dolinay</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Lam</surname>
<given-names>HC</given-names>
</name>
</person-group>
<article-title>Autophagy proteins regulate innate immune response by inhibiting NALP3 inflammasome-mediated mitochondrial DNA release</article-title>
<source/>Nat Immunol
          <year>2011</year>
<volume>12</volume>
<fpage>222</fpage>
<lpage>230</lpage>
<pub-id pub-id-type="pmid">21151103</pub-id>
</element-citation>
</ref>
<ref id="B48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harris</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hartman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Roche</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>O&amp;apos;Shea</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sharp</surname>
<given-names>FA</given-names>
</name>
</person-group>
<article-title>Autophagy controls IL-1beta secretion by targeting Pro-IL-1beta for degradation</article-title>
<source/>J Biol Chem
          <year>2011</year>
<volume>286</volume>
<fpage>9587</fpage>
<lpage>9597</lpage>
<pub-id pub-id-type="pmid">21228274</pub-id>
</element-citation>
</ref>
<ref id="B49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rathinam</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Vanaja</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Fitzgerald</surname>
<given-names>KA</given-names>
</name>
</person-group>
<article-title>Regulation of inflammasome signaling</article-title>
<source/>Nat Immunol
          <year>2012</year>
<volume>13</volume>
<fpage>333</fpage>
<lpage>342</lpage>
<pub-id pub-id-type="pmid">22430786</pub-id>
</element-citation>
</ref>
<ref id="B50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Nierop</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Stap</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Van Noorden</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>van Eijk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>de Groot</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Lysosomal destabilization contributes to apoptosis of germinal center B-lymphocytes</article-title>
<source/>J Histochem Cytochem
          <year>2006</year>
<volume>54</volume>
<fpage>1425</fpage>
<lpage>1435</lpage>
<pub-id pub-id-type="pmid">16957167</pub-id>
</element-citation>
</ref>
<ref id="B51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Repnik</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Stoka</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Turk</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Turk</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Lysosomes and lysosomal cathepsins in cell death</article-title>
<source/>Biochim Biophys Acta
          <year>2012</year>
<volume>1824</volume>
<fpage>22</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="pmid">21914490</pub-id>
</element-citation>
</ref>
<ref id="B52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>XM</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Dalen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lotem</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kama</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sachs</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Brunk</surname>
<given-names>UT</given-names>
</name>
</person-group>
<article-title>Lysosomal destabilization in p53-induced apoptosis</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2002</year>
<volume>99</volume>
<fpage>6286</fpage>
<lpage>6291</lpage>
<pub-id pub-id-type="pmid">11959917</pub-id>
</element-citation>
</ref>
<ref id="B53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mukhopadhyay</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Panda</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Sinha</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Bhutia</surname>
<given-names>SK</given-names>
</name>
</person-group>
<article-title>Autophagy and apoptosis Where do they meet?</article-title>
<source/>Apoptosis
          <year>2014</year>
<volume>19</volume>
<fpage>555</fpage>
<lpage>566</lpage>
<pub-id pub-id-type="pmid">24415198</pub-id>
</element-citation>
</ref>
<ref id="B54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lemmon</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Pleckstrin Homology (PH) domains and phosphoinositides</article-title>
<source/>Biochem Soc Symp
          <year>2007</year>
<issue>74</issue>
<fpage>81</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="pmid">17233582</pub-id>
</element-citation>
</ref>
<ref id="B55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Min</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Structure and function of WD40 domain proteins</article-title>
<source/>Protein Cell
          <year>2011</year>
<volume>2</volume>
<fpage>202</fpage>
<lpage>214</lpage>
<pub-id pub-id-type="pmid">21468892</pub-id>
</element-citation>
</ref>
<ref id="B56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burgess</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mornon</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>De saint-basile</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Callebaut</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>A concanavalin A-like lectin domain in the CHS1/LYST protein, shared by members of the BEACH family</article-title>
<source/>Bioinformatics
          <year>2009</year>
<volume>25</volume>
<fpage>1219</fpage>
<lpage>1222</lpage>
<pub-id pub-id-type="pmid">19289442</pub-id>
</element-citation>
</ref>
<ref id="B57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tuand</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Stijnen</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Volders</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Declercq</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nuytens</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Meulemans</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Nuclear localization of the autism candidate gene neurobeachin and functional interaction with the NOTCH1 intracellular domain indicate a role in regulating Transcription</article-title>
<source/>PLoS One
          <year>2016</year>
<volume>11</volume>
<issue>3</issue>
<elocation-id>e0151954</elocation-id>
<pub-id pub-id-type="pmid">26999814</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<sub-article article-type="Review Article" id="s1" xml:lang="es">
<front-stub>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articulo de Revisión</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>LRBA en el sistema de endomembranas</article-title>
</title-group>
</front-stub>
<body>
<sec>
<title>Introducción</title>
<p>Se han reportado más de 400 genes que afectan cuantitativa y/o cualitativamente y de manera sintomática el sistema inmune <xref ref-type="bibr" rid="B1"><sup>1</sup></xref>. Entre estos se encuentra <italic>LRBA</italic> (del inglés, <italic>Lipopolysaccharide-responsive and beige-like anchor protein)</italic>; las mutaciones homocigotas o heterocigotas compuestas en este gen, causan pérdida de la expresión de la proteína LRBA, lo que se asocia a un amplio espectro de manifestaciones clínicas e inmunológicas <xref ref-type="bibr" rid="B1"><sup>1</sup></xref>. El primer reporte sobre la deficiencia de LRBA fue realizado, en cinco pacientes procedentes de cuatro familias consanguíneas con hipogamaglobulinemia, con manifestaciones autoinmunes e infecciones recurrentes, <xref ref-type="bibr" rid="B2"><sup>2</sup></xref>. Posteriormente se han publicado varios reportes de individuos con deficiencia de la proteína LRBA los cuales presentaron un espectro más amplio de manifestaciones clínicas que incluyeron: una mayor susceptibilidad a las infecciones, poliautoinmunidad, linfoproliferación y gastropatía, todo ello asociado o no a hipogamaglobulinemia <xref ref-type="bibr" rid="B3"><sup>3</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B5"><sup>5</sup></xref> . También se reportó un individuo asintomático <xref ref-type="bibr" rid="B6"><sup>6</sup></xref>.</p>
<p>Con relación a los hallazgos inmunológicos, se observó que los linfocitos T de pacientes con deficiencia de LRBA presentaron un aumento en la apoptosis inducida por inanición o estaurosporina (un potente inhibidor de las proteinas-cinasas y activador de las caspasas) y controversialmente, una disminución en la apoptosis inducida por Fas <xref ref-type="bibr" rid="B7"><sup>7</sup></xref>. Además, se determinó en estas células una disminución en la expresión de CTLA-4 (del inglés <italic>Cytotoxic T-Lymphocyte Antigen 4</italic>), tanto en la membrana como a nivel intracelular <xref ref-type="bibr" rid="B8"><sup>8</sup></xref>. En los linfocitos B provenientes de pacientes se observó una disminución en la producción de anticuerpos <italic>in vitro</italic>, un incremento en la apoptosis y un defecto en la autofagia tras la inanición <xref ref-type="bibr" rid="B2"><sup>2</sup></xref>. En conjunto, estos estudios sugieren que LRBA es importante para la respuesta humoral, la regulación inmune y la defensa contra las infecciones, tanto de microorganismos extracelulares como intracelulares, influenciando la supervivencia y la homeostasis de los linfocitos T y B.</p>
</sec>
<sec>
<title>LRBA: características generales</title>
<p><italic>LRBA</italic> está localizado en el cromosoma 4q31.3, posee un tamaño de 750,839 pb y está organizado en 58 exones. La proteína posee 2,863 aminoácidos con un peso aproximado de ~319 KDa (<xref ref-type="fig" rid="f3">Fig. 1</xref>). En el ratón, se detectaron tres diferentes transcriptos de 1344, 836 y 787 pb que se expresan diferencialmente en los tejidos <xref ref-type="bibr" rid="B9"><sup>9</sup></xref>. Adicionalmente, la expresión del ARN mensajero (ARNm) de <italic>LRBA</italic> se incrementó entre dos y cuatro veces luego de la estimulación con lipopolisacárido (LPS) en líneas celulares <xref ref-type="bibr" rid="B9"><sup>9</sup></xref>.</p>
<p>
<fig id="f3" orientation="portrait" position="float"><label> Figura 1</label><caption><title>Representación esquemática del LRBA y la proteína que codifica. El LRBA humano contiene 750,839 pb organizado en 58 exones. Su ubicación citogenética es 4q31.3. La proteína humana LRBA tiene 2,863 aminoácidos compuestos de múltiples dominios. El peso molecular predicho es de 319 kD. </title></caption><graphic xlink:href="1657-9534-cm-49-03-00236-gf3"></graphic></fig>
</p>
<p>Esta proteína posee diferentes dominios, entre ellos el más caracterizado es el dominio BEACH (Del inglés, <italic>beige</italic> and Chediak-Higashi). Este dominio, de aproximadamente ~280 aminoácidos, se conserva en varias proteínas agrupadas como familia BDCP (Del inglés<italic>, BEACH domain containing proteins</italic>) <xref ref-type="bibr" rid="B10"><sup>10</sup></xref>, en las cuales se localiza generalmente hacia el extremo C-terminal <sup>(</sup><xref ref-type="bibr" rid="B11"><sup>11</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B12"><sup>12</sup></xref>. La función de este dominio es desconocida y su secuencia no presenta homología con ninguna proteína en la base de datos del proteoma humano <sup>(</sup><xref ref-type="bibr" rid="B11"><sup>11</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B12"><sup>12</sup></xref>. Además del dominio BEACH, las BDCP comparten los dominios ConA-like (del inglés, <italic>concanavalin A-like</italic>), PH (del inglés, <italic>Pleckstrin homology</italic>) y WD40 (repeticiones de triptófano y ácido aspártico. Por su parte, el dominio DUF1088 (del inglés, <italic>domain of unknown function 1088</italic>) es compartido solo por LRBA y su parálogo Neurobeachin, lo cual podría indicar una función específica de estas dos proteínas no compartida por otros miembros de las BDCP.</p>
<p>Además de estos dominios, LRBA parece contener un dominio VHS (del inglés, <italic>VPS</italic> (<italic>vacuolar protein sorting</italic>)<italic>-27, Hrs</italic> (<italic>hepatocyte growth factor-regulated tyrosine kinase sustrate</italic>) <italic>STAM</italic> (<italic>signal transducing adaptor molecule</italic>) <sup>(</sup><xref ref-type="bibr" rid="B13"><sup>13</sup></xref>. Las posibles funciones de estos dominios se explican en la <xref ref-type="table" rid="t2">Tabla 1</xref>. </p>
<p>
<table-wrap id="t2" orientation="portrait" position="float"><label>Tabla 1</label><caption><title>Características generales de los dominios de la proteín LRBA.</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Dominio</th><th align="left" colspan="1" rowspan="1">Características</th><th align="left" colspan="1" rowspan="1">Referencia </th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">BEACH</td><td align="left" colspan="1" rowspan="1">Está presente en proteínas implicadas en el tráfico de vesículas, dinámica de membranas y señalización de receptores.</td><td align="left" colspan="1" rowspan="1">
<xref ref-type="bibr" rid="B12"><sup>12</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B13"><sup>13</sup></xref>
</td></tr><tr><td align="left" colspan="1" rowspan="1">PH</td><td align="left" colspan="1" rowspan="1">Interactúa con fosfatidil-inositol dentro de membranas biológicas, proteínas G hetero-triméricas y proteína quinasa C. Esto permite el direccionamiento apropiado de proteínas a diferentes compartimentos celulares o la activación de vías de transducción de señales.</td><td align="left" colspan="1" rowspan="1">
<xref ref-type="bibr" rid="B54"><sup>54</sup></xref>
</td></tr><tr><td align="left" colspan="1" rowspan="1">WD40</td><td align="left" colspan="1" rowspan="1">Implicado en transducción de señales, control del ciclo celular y la apoptosis. Sitio para la interacción transitoria proteína-proteína o para el ensamblaje de complejos proteicos.</td><td align="left" colspan="1" rowspan="1">
<xref ref-type="bibr" rid="B55"><sup>55</sup></xref>
</td></tr><tr><td align="left" colspan="1" rowspan="1">ConA-like</td><td align="left" colspan="1" rowspan="1">Participa en el tráfico y distribución de proteínas por vías secretoras.</td><td align="left" colspan="1" rowspan="1">
<xref ref-type="bibr" rid="B56"><sup>56</sup></xref>
</td></tr><tr><td align="left" colspan="1" rowspan="1">DUF1088</td><td align="left" colspan="1" rowspan="1">La función de este dominio es desconocida. Sin embargo, una secuencia de penta-arginina localizada en el dominio DUF1088 de Neurobeachin fue identificada como una señal potencial de localización nuclear.</td><td align="left" colspan="1" rowspan="1">
<xref ref-type="bibr" rid="B57"><sup>57</sup></xref>
</td></tr><tr><td align="left" colspan="1" rowspan="1">VHS</td><td align="left" colspan="1" rowspan="1">Encontrado en la porción N terminal de proteínas asociadas con endocitosis y/o tráfico vesicular. Posiblemente funciona como un dominio adaptador que ayuda a localizar las proteínas en la membrana celular o en membranas de la maquinaria endocítica.</td><td align="left" colspan="1" rowspan="1">
<xref ref-type="bibr" rid="B13"><sup>13</sup></xref>
</td></tr></tbody></table></table-wrap>
</p>
<p>Con respecto a la expresión específica de tejido, se han observado transcriptos de esta proteína principalmente en células de médula ósea, nódulo linfático, bazo, hígado fetal, placenta, riñón y páncreas por medio de RT-PCR (del inglés, <italic>Reverse transcription polymerase chain reaction</italic>) y qPCR (del inglés, <italic>quantitative polymerase chain reaction</italic>) <xref ref-type="bibr" rid="B2"><sup>2</sup></xref>. De manera interesante, la expresión de esta proteína no se limita a tejidos del sistema inmune, e incluso su expresión se ve considerablemente aumentada en tejidos provenientes de varios tipos de cáncer <xref ref-type="bibr" rid="B14"><sup>14</sup></xref>. Estos hallazgos sugieren que la función de LRBA está más relacionada con mecanismos celulares básicos de crecimiento, desarrollo y supervivencia. A nivel subcelular, utilizando una sonda dirigida contra el dominio BEACH de LRBA, se observó esta proteína en el citosol, aparato de Golgi y algunos lisosomas en la línea celular de macrófagos murinos RAW264.7 estimulados con LPS <xref ref-type="bibr" rid="B9"><sup>9</sup></xref>. Además, con la utilización del microscopio electrónico, se observó que LRBA se localizó en el retículo endoplásmico, la membrana plasmática y las vesículas de endocitosis asociadas a clatrina en estas mismas células <xref ref-type="bibr" rid="B9"><sup>9</sup></xref>.</p>
</sec>
<sec>
<title>Función del LRBA</title>
<sec>
<title>LRBA participa en el tráfico vesicular y reciclaje de receptores.</title>
<p>CTLA-4 (Del inglés <italic>Cytotoxic T-Lymphocyte Antigen</italic> 4) es un receptor proteico situado en la membrana celular de los linfocitos T activados. Su función es regular la homeostasis y la tolerancia inmunológica periférica inhibiendo la activación de los linfocitos T, por competición con la molécula coestimuladora CD28, mediante la unión a los ligandos CD80 y CD86, los cuales se expresan en la superficie de las células presentadoras de antígeno <xref ref-type="bibr" rid="B15"><sup>15</sup></xref>. Mientras que CD28 reside principalmente en la superficie celular, CTLA-4 se localiza primero en los compartimentos intracelulares como el aparato de Golgi, los endosomas, los gránulos secretores y las vesículas lisosomales. La estimulación del TCR (del inglés, <italic>T cell receptor</italic>) promueve el tráfico de CTLA-4 desde los compartimentos vesiculares hacia la membrana celular, sin embargo, en la membrana, este receptor es continuamente endocitado dentro de las vesículas cubiertas de clatrina. Una vez endocitadas, algunas moléculas de CTLA-4 son recicladas a la membrana celular, mientras que otras son rápidamente degradadas en los compartimentos lisosomales <xref ref-type="bibr" rid="B16"><sup>16</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B17"><sup>17</sup></xref>. CTLA-4 contiene una pequeña cola citoplasmática con dos motivos de tirosina en la posición Y<sub>201</sub>VKM y Y<sub>218</sub>FIP. Diversas proteínas intracelulares se unen al motivo Y<sub>201</sub>VKM, incluyendo AP-1 y AP-2 (del inglés <italic>clathrin-associated adaptor</italic>). AP-2 media la internalización de CTLA-4 desde la superficie celular a los endosomas y los compartimentos lisosomales, mientras que AP-1 regula en el tráfico de CTLA-4 desde el aparato de Golgi a los compartimentos endosomales y lisosomas para su degradación <xref ref-type="bibr" rid="B17"><sup>17</sup></xref>. En un estudio reciente, se demostró que la proteína LRBA es necesaria para el tráfico vesicular de CTLA-4 hacia la membrana plasmática <xref ref-type="bibr" rid="B8"><sup>8</sup></xref>. Cuando CTLA-4 es requerida en la membrana, LRBA regula el reciclaje de CTLA-4 desde los endosomas a la membrana celular ayudando a mantener los niveles intracelulares de CTLA-4 para su inmediata movilización a la membrana. De esta manera, una deficiencia de LRBA favorece una rápida degradación de CTLA-4 en los compartimentos lisosomales, con su consecuente disminución tanto intracelular como extracelularmente <xref ref-type="bibr" rid="B8"><sup>8</sup></xref>. Este trabajo también demostró que LRBA interactúa por medio del dominio ConA-<italic>like</italic> y el dominio PH-BEACH con la cola citoplasmática de CTLA-4, específicamente con el motivo Y<sub>201</sub>VKM. Finalmente, el silenciamiento de AP-1, pero no AP-2 puede rescatar parcialmente la pérdida CTLA-4 en las células deficientes de LRBA. Estos resultados sugieren que LRBA bloquea el tráfico de CTLA-4 a los lisosomas, compitiendo con AP-1 por la unión a este motivo <xref ref-type="bibr" rid="B8"><sup>8</sup></xref>. Hallazgos recientes indicaron que los linfocitos CD4+ Foxp3+ provenientes de células del bazo de ratones deficientes para LRBA también exhiben una disminución intracelular de CTLA-4 <xref ref-type="bibr" rid="B18"><sup>18</sup></xref>.</p>
<p>Otro estudio que ilustró el papel de LRBA en el tráfico vesicular fue realizado con el receptor del factor de crecimiento epidermal (EGFR, del inglés, <italic>epidermal growth factor receptor</italic>). Mutantes dominantes negativas para LRBA disminuyeron la expresión y fosforilación de EGFR <xref ref-type="bibr" rid="B14"><sup>14</sup></xref>. El EGFR es un receptor tirosina kinasa el cual se expresa en una gran variedad de tejidos, interactuando no sólo con el EGF sino también con TGF-( (Del inglés, <italic>Transforming growth factor-(</italic>), y otros ligandos. Esto induce la dimerización y trans-auto-fosforilación del receptor, reclutando proteínas que activan las vías de señalización necesarias para la proliferación, la diferenciación, el crecimiento, la migración e la inhibición de la apoptosis <xref ref-type="bibr" rid="B19"><sup>19</sup></xref>. En los linfocitos, al igual que CTLA-4, su expresión en la superficie celular es regulada por la endocitosis mediada por clatrina, lo cual conduce ya sea a su degradación por vía lisosomal o a su reciclaje a la superficie celular <xref ref-type="bibr" rid="B20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref>. Defectos en el tráfico vesicular de este receptor resultan en una localización aberrante, lo cual potencia la señalización permitiendo el desarrollo de cáncer <xref ref-type="bibr" rid="B22"><sup>22</sup></xref>. Aunque no se conoce si LRBA y EGFR interactúan físicamente, se ha comprobado que AP-2 facilita la endocitosis y el tráfico de EGFR por la vía endocítica <xref ref-type="bibr" rid="B3"><sup>3</sup></xref>.</p>
<p>Finalmente, en pacientes deficientes de LRBA se demostró una disminución en la apoptosis mediada por el receptor de muerte Fas, cuando se comparó con los individuos sanos <xref ref-type="bibr" rid="B6"><sup>6</sup></xref>. El receptor Fas promueve la apoptosis por la vía extrínseca, después de la unión al ligando de Fas (FasL). Posterior a la unión Fas/FasL, se da un proceso de internalización del receptor, similar a lo que ocurre con EGFR, el cual es crucial para desencadenar la apoptosis <xref ref-type="bibr" rid="B24"><sup>24</sup></xref>. Hasta la fecha, se desconoce si existen alteraciones en la cantidad de receptores Fas en la membrana celular en pacientes con deficiencia en LRBA, pero el incremento de FasL en suero en dichos pacientes podría sugerir que posiblemente la deficiencia de LRBA tenga un efecto en el receptor Fas similar al de CTLA-4, regulando su tráfico ya sea hacia la membrana celular o lisosomas <xref ref-type="bibr" rid="B25"><sup>25</sup></xref>. </p>
<p>Estas evidencias nos llevan también a preguntarnos si LRBA estaría implicado en el tráfico vesicular de otros receptores en linfocitos?. En ratones deficientes para LRBA se ha reportaron defectos en la fosforilación de ERK1/2 (del inglés, <italic>extracellular signal-regulated kinases</italic>) y AKT en células NK (del inglés, <italic>natural killer</italic>) estimuladas con anticuerpos anti-NKG2D o anti-NKp46, con una disminución significativa en la producción de IFN-gamma después de estos estímulos <xref ref-type="bibr" rid="B26"><sup>26</sup></xref>. Aunque en este estudio no se determinaron los niveles de expresión de estos receptores en los ratones deficientes de LRBA, existen algunas evidencias que indican que la exposición a sus ligandos específicos, induce la degradación de NKG2D y DAP10, la molécula adaptadora intracelular de este receptor en los lisosomas <xref ref-type="bibr" rid="B27"><sup>27</sup></xref>. Esta regulación parece ser mediada por clatrina <xref ref-type="bibr" rid="B28"><sup>28</sup></xref>. No se conoce si LRBA está involucrado en el tráfico intracelular de estos receptores en células NK. De la misma manera, considerando que la deficiencia de LRBA conlleva a defectos en las respuestas de anticuerpos, es importante considerar también, si esta molécula regula la expresión y función de otros receptores cuya expresión es modulada por compartimentos vesiculares, procesos determinantes para la activación del linfocito B <xref ref-type="bibr" rid="B29"><sup>29</sup></xref>. </p>
<p>A pesar de los estudios sobre la modulación de algunos receptores celulares mediada por LRBA, es poco lo que se conoce sobre las vías de tráfico intracelular utilizadas por esta molécula para realizar dicha función. Se ha descrito que dicho transporte se realiza mediante el reclutamiento de proteínas en vesículas recubiertas por clatrina, en el cual el receptor es removido a endosomas tempranos y posteriormente degradado por enzimas lisosomales o reciclado a la superficie celular <xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. AP-1 se considera necesario para este transporte. La localización de AP-1 en el aparato de Golgi y en endosomas, depende de su unión directa a Arf (del inglés: <italic>ADP-ribosylation factor</italic>)-1 y específicamente en endosomas de reciclaje, a Arf-6, entre otros complejos proteicos <xref ref-type="bibr" rid="B31"><sup>31</sup></xref>. Como ya se mencionó, LRBA inhibe la degradación de CTLA-4 en lisosomas por competición con AP-1, demostrando ser necesario para la movilización a estos compartimientos <xref ref-type="bibr" rid="B8"><sup>8</sup></xref>. Sin embargo, la relación de LRBA con toda la vía endosomal no es clara. El reciclaje de receptores depende además de los compartimientos vesiculares, de proteínas involucradas incluidas las Arf, de enzimas como la fosfolipasa D y de las proteínas Rab. De manera interesante, un estudio realizado en <italic>Drosophila</italic>, sugiere una posible interacción funcional entre bchs (del inglés <italic>blue cheese</italic>), un miembro de la familia BEACH, y Rab11 <xref ref-type="bibr" rid="B32"><sup>32</sup></xref>. Estos hallazgos sugieren que, así como Rab11, Bchs podría ser un regulador del tráfico de las vesículas. </p>
<p>Por lo tanto, son necesarios estudios que cuantifiquen la expresión de los receptores mencionados en células deficientes de LRBA (silenciadas o provenientes de pacientes). También sería útil el uso de técnicas avanzadas de microscopía, con lo cual se pudiera demostrar la localización de LRBA en otras organelas involucradas en este tipo de tráfico. Además, estudios de co-inmunoprecipitación entre LRBA y las proteínas de tráfico vesicular, el uso de drogas que bloqueen este tráfico o la implementación de dominantes negativos de ARFs, fosfolipasa D o las Rab, podrían ampliar nuestro conocimiento sobre la interacción de LRBA con otras moléculas de tráfico vesicular y así determinar su relación con la expresión en membrana de receptores como EGFR, Fas o los receptores activadores de las células NK, linfocitos B u otros en células inmunes.</p>
</sec>
<sec>
<title>LRBA es una molécula implicada en autofagia</title>
<p>La autofagia es un mecanismo de degradación lisosomal por el cual la célula destruye organelas dañadas y microorganismos y ayuda a reciclar macromoléculas. En este proceso se forma una doble membrana de aislamiento o fagóforo cerca al blanco, que luego se elonga, rodeándolo, para posteriormente madurar con la asimilación de una carga citosólica formando el autofagosoma. Para que la maduración sea efectiva, el autofagosoma se debe fusionar con los endosomas tempranos o tardíos formando una estructura llamada anfisoma <xref ref-type="bibr" rid="B33"><sup>33</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B34"><sup>34</sup></xref>. Por último, el autofagosoma maduro se fusiona con el lisosoma para permitir la degradación de su contenido por las proteasas lisosómicas y enzimas hidrolíticas <xref ref-type="bibr" rid="B35"><sup>35</sup></xref>.</p>
<p>Cuando estudiamos los genes homólogos de <italic>LRBA</italic>, encontramos que varios de ellos están implicados en la autofagia. <italic>WDFY3</italic> (del inglés - <italic>WD and FYVE zinc finger domain containing protein 3</italic>), codifica una proteína que colocaliza con marcadores de autofagosomas <xref ref-type="bibr" rid="B36"><sup>36</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B37"><sup>37</sup></xref>. Además, su dominio PH-BEACH interacciona con la proteína p62 <xref ref-type="bibr" rid="B34"><sup>34</sup></xref>. P62 es una proteína localizada en los sitios de formación de los autofagosomas y se asocia tanto con LC3 (Del inglés, <italic>microtubule-associated protein 1A/1B-light chain 3</italic>) como con proteínas ubiquitinadas <xref ref-type="bibr" rid="B34"><sup>34</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B38"><sup>38</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B39"><sup>39</sup></xref>. LC3 es una proteína citosólica que cuando se conjuga con una fosfatidiletanolamina es reclutada a la membrana del autofagosoma favoreciendo el flujo autofágico <xref ref-type="bibr" rid="B34"><sup>34</sup></xref>. Por otro lado, defectos en el gen ortólogo de <italic>LYST</italic>, mauve (mv) en <italic>Drosophila</italic>, afecta la función de autofagosomas <xref ref-type="bibr" rid="B40"><sup>40</sup></xref>. </p>
<p>En células B inmortalizadas provenientes de pacientes con deficiencia de LRBA se observó una reducción significativa en el proceso de autofagia en respuesta a la inanición, además hubo un incremento en el área del aparato de Golgi, una acumulación de los autofagosomas y la presencia de centriolos, al compararse con las células provenientes de un individuo sano <xref ref-type="bibr" rid="B2"><sup>2</sup></xref>. Estos resultados sugieren que el flujo de la autofagia está deteriorado en la deficiencia de LRBA, un hallazgo que fue demostrado por una fusión deficiente del autofagosoma a los lisosomas en linfocitos B inmortalizados de pacientes deficientes de LRBA, sometidos a inanición <xref ref-type="bibr" rid="B2"><sup>2</sup></xref>. Sin embargo, ¿cuál son las posibles funciones de LRBA en los procesos de autofagia? Considerando que tanto el tráfico de receptores de superficie celular como la autofagia necesitan de vesículas endocíticas, y que LRBA posiblemente se encuentra ubicado en estas vesículas, una posible hipótesis es que LRBA facilite la fusión entre el autofagosoma y el endosoma tardío y, por consiguiente, la formación del anfisoma. Uno de los marcadores de los endosomas tardíos es Rab7 y se ha demostrado en células CHO transfectadas con la mutante dominante negativa de Rab7, T22N, que esta molécula se requiere para la formación de los anfisomas <xref ref-type="bibr" rid="B33"><sup>33</sup></xref>. Otra hipótesis que se podría considerar es que, de la misma manera que con el tráfico vesicular de CTLA-4, también en el contexto de autofagia en linfocitos, LRBA compita con proteínas adaptadoras de clatrina, regulando este proceso. Esto ya que se ha observado, que moléculas como clatrina y sus proteínas adaptadoras son también importantes para el flujo autofágico <xref ref-type="bibr" rid="B41"><sup>41</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B42"><sup>42</sup></xref>. Por otra parte, herramientas <italic>in silico</italic> han predicho que LRBA interactúa con LC3 <xref ref-type="bibr" rid="B13"><sup>13</sup></xref>.</p>
<p>En un intento por asociar los defectos en la autofagia con las características clínicas encontradas en los individuos con deficiencia de LRBA, es importante tener en cuenta que una de las manifestaciones clínicas más comunes entre estos individuos es la gastropatía, en muchos casos expresada como Enfermedad Inflamatoria Intestinal (EII) o enfermedad similar a EII, una condición que se caracteriza por una inflamación recurrente destructiva en el tracto intestinal <xref ref-type="bibr" rid="B3"><sup>3</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B5"><sup>5</sup></xref>. Un incremento en la producción de IL-1β en la mucosa intersticial se ha involucrado con la inflamación descontrolada en esta enfermedad <xref ref-type="bibr" rid="B43"><sup>43</sup></xref>. Los macrófagos derivados de ratones deficientes para <italic>ATG16L1</italic> (del inglés, <italic>autophagy-related 16-like 1</italic>), los cuales presentan un defecto en la autofagia, muestran una elevada producción de IL-1β después de la estimulación con LPS <xref ref-type="bibr" rid="B44"><sup>44</sup></xref>. De la misma manera, el polimorfismo rs2241880 en <italic>ATG16L1</italic> incrementó la producción de IL-1β en células mononucleares de sangre periférica aisladas de pacientes con EII <xref ref-type="bibr" rid="B45"><sup>45</sup></xref>. La autofagia puede regular la producción de IL-1β mediante dos vías: en ausencia de autofagia, las mitocondrias defectuosas se acumulan generando un incremento de ROS (del inglés, <italic>reactive oxygen species</italic>) y liberando ADN mitocondrial al citoplasma, eventos que activan el inflamosoma, aumentando la producción de IL-1β <xref ref-type="bibr" rid="B46"><sup>46</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B47"><sup>47</sup></xref>. Por otra parte, la degradación de la pro-IL-1β mediada por los procesos de autofagia limita el sustrato disponible para el inflamasoma, regulando de esta manera la activación de la IL-1β <xref ref-type="bibr" rid="B48"><sup>48</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B49"><sup>49</sup></xref>. Por lo tanto, las alteraciones en la autofagia limitarían este mecanismo, aumentando los niveles de IL-1β e induciendo inflamación. No se conoce si las manifestaciones intestinales en los pacientes con deficiencia en LRBA están mediadas por una excesiva actividad del inflamosoma y la exagerada producción de IL-1β. </p>
<p>Se requieren estudios de microscopia con células deficientes de LRBA que estudien la distribución intracelular de moléculas como Rab7 y LC3 tras el flujo autofágico. Sería interesante también investigar si LRBA interactúa físicamente con alguna de las moléculas Rab involucradas en los diferentes tipos de autofagia, por medio de ensayos de co-inmunoprecipitación. El papel de LRBA en la actividad del inflamosoma pudiera abordarse mediante la medición de la producción de IL-1β en células fagocíticas o del epitelio intestinal deficientes de LRBA o determinando la actividad del auto-inflamosoma activo por medio de redistribución de ASC (del inglés, <italic>apoptosis-associated speck-like protein containing a caspase-recruitment domain</italic>), la cual es una proteína que recluta las caspasas necesarias en para la activación del inflamosoma. </p>
</sec>
<sec>
<title>LRBA participa en la apoptosis</title>
<p>En linfocitos B inmortalizados sometidos a inanición provenientes de pacientes deficientes de LRBA, se observó un incremento significativo de la apoptosis <xref ref-type="bibr" rid="B2"><sup>2</sup></xref>. Adicionalmente, en células HeLa silenciadas para LRBA expuestas a luz ultravioleta o estaurosporina, se observó un mayor clivaje de PARP (por sus siglas en inglés, <italic>Poly (ADP-ribose) polymerase</italic>) y de la caspasa 3, eventos necesarios para iniciar la cascada de señalización que finalmente lleva a la apoptosis <xref ref-type="bibr" rid="B14"><sup>14</sup></xref>.</p>
<p>La apoptosis es un tipo de muerte celular programada por la misma célula con el fin de controlar su desarrollo y crecimiento. Por mucho tiempo se ha considerado a las caspasas como las proteasas involucradas en la ejecución del programa de apoptosis, y hoy en día se conoce que la desestabilización parcial de la membrana lisosomal, con la consecuente liberación de enzimas hidrolíticas, puede iniciar y ejecutar el programa de apoptosis, activando las caspasas <xref ref-type="bibr" rid="B50"><sup>50</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B51"><sup>51</sup></xref>. En los centros germinales provenientes de amígdalas se observó que la desestabilización lisosomal en linfocitos B contribuye a la apoptosis <xref ref-type="bibr" rid="B50"><sup>50</sup></xref>. La inducción del daño lisosomal en estos linfocitos B resultó en el clivaje de la caspasa 8 y también del ADN, debido a la actividad incrementada de la catepsina B en el citoplasma. De manera interesante, se ha observado que p53 induce desestabilización lisosomal <xref ref-type="bibr" rid="B52"><sup>52</sup></xref> y el promotor de <italic>LRBA</italic> es regulado negativamente por p53 <xref ref-type="bibr" rid="B14"><sup>14</sup></xref>. <italic>P53</italic> es un gen supresor de tumores que codifica un factor de transcripción nuclear cuya expresión se incrementa en respuesta al daño, deteniendo el ciclo celular y facilitando la reparación del ADN o induciendo apoptosis <xref ref-type="bibr" rid="B52"><sup>52</sup></xref>. Se podría plantear la hipótesis que en ausencia de <italic>LRBA</italic>, p53 induce desestabilización lisosomal y como consecuencia la apoptosis en linfocitos. Sin embargo, hasta el momento no se conoce el mecanismo por el cual p53 induce la desestabilización lisosomal ni como LRBA protege las células de la apoptosis. </p>
<p>No obstante, parece existir una conexión entre los mecanismos de autofagia y la apoptosis. Aunque la diafonía entre los procesos de autofagia y la apoptosis es compleja también es crítica para el destino celular. Bajo ciertas condiciones celulares, la autofagia puede promover la supervivencia celular y evitar la apoptosis <xref ref-type="bibr" rid="B53"><sup>53</sup></xref>. Por ejemplo, el aumento de la autofagia en células privadas de nutrientes o factores de crecimiento permite la supervivencia celular al inhibir la apoptosis. Un mecanismo sugerido por el cual la autofagia inhibe la apoptosis, es el secuestro de las mitocondrias dañadas por el autofagosoma, evitando así que el citocromo c mitocondrial liberado sea capaz de formar un apoptosoma funcional en el citoplasma <xref ref-type="bibr" rid="B53"><sup>53</sup></xref>. Sin embargo, en otras condiciones, la autofagia puede culminar en la muerte celular, de manera dependiente o independiente de la apoptosis <xref ref-type="bibr" rid="B53"><sup>53</sup></xref>. Adicionalmente, son varias las proteínas que comparten un papel dual tanto en la apoptosis como en la autofagia <xref ref-type="bibr" rid="B53"><sup>53</sup></xref>. Estas proteínas autofágicas regulan positivamente o negativamente la apoptosis mitocondrial directa o indirectamente a través del clivaje de proteasas <xref ref-type="bibr" rid="B53"><sup>53</sup></xref>. En el contexto de las células deficientes de LRBA, se ha demostrado una autofagia defectuosa con un aumento en la apoptosis. No se conoce si una alteración en la depuración de las mitocondrias dañadas o un exagerado clivaje de las proteasas son los responsables de este fenotipo celular. </p>
<p>Por lo tanto, es necesario evaluar la cantidad y la integridad de los lisosomas en las células inmunes deficientes de LRBA. Además, se pudiera estimar la cinética de desestabilización lisosomal en relación con la cinética de otros parámetros apoptóticos como, inestabilidad mitocondrial, activación de caspasa-3 y escisión de ADN.</p>
</sec>
</sec>
<sec>
<title>Conclusión </title>
<p>En la última década se ha generado una gran cantidad de nueva información sobre la asociación de LRBA con el sistema inmune, su localización celular y su función. Esto ha impulsado nuestra comprensión de su papel en los procesos como el tráfico vesicular, la autofagia y la apoptosis. Sin embargo, muchas preguntas quedan por responder. Primero, ¿Está LRBA localizado en el sistema de endomembranas? ¿Forma LRBA complejos proteicos con otras proteínas como las Rab o las Arf? ¿modula LRBA el tráfico de receptores como Fas, NKG2D o NKp46? Hay evidencia de que LRBA evita la degradación de CTLA-4 por competición de AP-1 en linfocitos T reguladores humanos, una proteína que interactúa con Arf1 y Arf6. Además, el gen ortólogo <italic>Bchs</italic> en <italic>Drosophila</italic> modela el tráfico dependiente de Rab11. Esto plantea la posibilidad de que LRBA module varios receptores inmunes mediante el tráfico de vesículas y, por lo tanto, sea determinante en el desarrollo normal de la respuesta inmune. </p>
<p>En segundo lugar, aunque se ha determinado que los defectos en LRBA conlleva a una autofagia deficiente, ¿cuáles son las funciones de esta proteína en estos procesos?, ¿Cuál es su localización en autofagosoma, anfisomas, autofagolisomas?, ¿interactua LRBA físicamente con moléculas implicadas en la autofagia como LC3, ATG o Rab7?, Al estudiar el tráfico vesicular y la autofagia encontramos una conexión medida por Rab7, el cual se necesita para la fusión entre los endosomas tardíos y el autofagolisosoma, por lo que es posible pensar que LRBA puede ser requerido para la fusión entre estas dos organelas. </p>
<p>En tercer lugar, ¿puede la deficiencia de LRBA afectar la estabilidad lisosomal y de este modo desencadenar la apoptosis? Se sabe de la interacción de LRBA con estas vesículas, sin embargo, los mecanismos que subyacen a su función en este contexto, aún no se han dilucidado por completo. </p>
<p>Finalmente, la asociación entre el tráfico endosomal, la autofagia, la apoptosis y la proteína LRBA aún no se han abordado. Sin embargo, con base a lo expuesto en esta revisión nosotros proponemos un modelo de LRBA en el tráfico de CTLA-4 (<xref ref-type="fig" rid="f4">Fig. 2</xref>). Una comprensión completa de la función LRBA también requiere una disección detallada de su estructura. Es necesario caracterizar la función de sus dominios en la interacción con otras proteínas y en general, en la homeostasis celular.</p>
<p>
<fig id="f4" orientation="portrait" position="float"><label>Figura 2</label><caption><title>LRBA en la regulación del tráfico vesicular.CTLA-4 es un receptor situado en la membrana de los linfocitos T activados. Este receptor es internalizado en vesículas recubiertas de clatrina mediante su interacción con AP2. LRBA regula el reciclaje de CTLA-4 desde los endosomas a la membrana celular, impidiendo su degradación en los compartimentos lisosomales. Los procesos de autofagia también necesitan de las vesículas endocíticas. LRBA se encuentra ubicado en estas vesículas y podría interaccionar con moléculas aún no identificadas para facilitar la fusión entre el autofagosoma y el endosoma tardío. </title></caption><graphic xlink:href="1657-9534-cm-49-03-00236-gf4"></graphic></fig>
</p>
<p>Se espera que las nuevas tecnologías de microscopia avanzada, de edición genética como CRISPR/Cas9 o la genómica, y los nuevos conceptos como transcriptoma, proteoma, metaboloma, epigenoma, ayuden a resolver muchas de estas preguntas para delucidar el papel de esta proteína y plantear estrategias para su regulación.</p>
</sec>
</body>
</sub-article>
</article>
</pmc-articleset>